{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+2%2FMTD&page=48",
    "query": {
      "intervention": "Dose level 2/MTD",
      "page": 48
    },
    "page_size": 10
  },
  "pagination": {
    "page": 48,
    "page_size": 10,
    "total_count": 1606,
    "total_pages": 161,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+2%2FMTD&page=49&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+level+2%2FMTD&page=47&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:12:26.826Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02525029",
      "title": "Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Graft vs Host Disease"
      ],
      "interventions": [
        {
          "name": "Pregnyl®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "Up to 76 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-03",
      "completion_date": "2022-04",
      "has_results": true,
      "last_update_posted_date": "2023-12-14",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02525029"
    },
    {
      "nct_id": "NCT04294160",
      "title": "A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BRAF V600 Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "LTT462",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "LXH254",
          "type": "DRUG"
        },
        {
          "name": "TNO155",
          "type": "DRUG"
        },
        {
          "name": "Spartalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tislelizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2020-07-22",
      "completion_date": "2024-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04294160"
    },
    {
      "nct_id": "NCT01228760",
      "title": "A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Neoplasms"
      ],
      "interventions": [
        {
          "name": "ASG-5ME",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 46,
      "start_date": "2010-10",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2013-06-07",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Detriot, Michigan • New York, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detriot",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01228760"
    },
    {
      "nct_id": "NCT04185220",
      "title": "Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult T-Cell Lymphoma/Leukemia",
        "Sezary Syndrome",
        "Mycosis Fungoides"
      ],
      "interventions": [
        {
          "name": "Recombinant human Interleukin-15 (rhIL-15)",
          "type": "DRUG"
        },
        {
          "name": "Mogamulizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-02-26",
      "completion_date": "2022-05-18",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04185220"
    },
    {
      "nct_id": "NCT00004190",
      "title": "Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "1999-10",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004190"
    },
    {
      "nct_id": "NCT01440582",
      "title": "Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Symptom Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2013-02-18",
      "completion_date": "2019-02-28",
      "has_results": false,
      "last_update_posted_date": "2019-03-04",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01440582"
    },
    {
      "nct_id": "NCT00455052",
      "title": "A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "XMT-1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mersana Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-03",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Indianapolis, Indiana + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00455052"
    },
    {
      "nct_id": "NCT03143985",
      "title": "Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Vactosertib",
          "type": "DRUG"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Koen van Besien",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2017-07-21",
      "completion_date": "2022-09-01",
      "has_results": false,
      "last_update_posted_date": "2024-05-24",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03143985"
    },
    {
      "nct_id": "NCT06723236",
      "title": "A Study of MGC028 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "NSCLC Adenocarcinoma",
        "Cholangiocarcinoma",
        "Pancreatic Carcinoma",
        "Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "MGC028",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2025-02-13",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06723236"
    },
    {
      "nct_id": "NCT03119064",
      "title": "BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Glioblastoma",
        "GBM"
      ],
      "interventions": [
        {
          "name": "Nanoliposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-11-30",
      "completion_date": "2021-10-08",
      "has_results": true,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-11-19T07:12:26.826Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03119064"
    }
  ]
}